

Transmittal 21-10: Chronic Hepatitis C Treatment Coverage Policy: Removal of Minimum Fibrosis Score Requirement.

To All MedStar Family Choice-DC Contracted Providers:

The District Medicaid program implemented a policy change effective March 1, 2021 for orally administered Direct Acting Antivirals (DAAs) used in the current treatment of chronic Hepatitis C infection for Medicaid [Fee for Service (FFS) and managed care (MCO)] enrolled beneficiaries.

In support of the District's goal of eliminating Hepatitis C and enabling access to curative treatment as a critical step in achieving equitable outcomes for Medicaid beneficiaries, MFC-DC will eliminate the minimum fibrosis score requirement for preferred orally administered Direct Acting Antiviral medications:

- **Mavyret®** (glecaprevir and pibrentasvir)
- **Vosevi®** (sofosbuvir, velpatasvir, and voxilaprevir)

For questions concerning this transmittal from the DHCF, please contact the MFC-DC Provider Relations department, Monday through Friday, 8 a.m. to 5:30 p.m.

Phone: 855-798-4244, Option 2

Email: mfc-dc-providerrelations@medstar.net

GOVERNMENT OF THE DISTRICT OF COLUMBIA
Department of Health Care Finance



Office of the Senior Deputy Director/
Medicaid Director

Transmittal# 21-10

To: All DC Medicaid Providers

From: Melisa Byrd
Senior Deputy Director and State Medicaid Director

Date: March 1, 2021

Subject: Chronic Hepatitis C Treatment Coverage Policy: Removal of Minimum Fibrosis Score Requirement for Mavyret® and Vosevi®

Purpose

The purpose of this transmittal is to outline the policy change that the District Medicaid program will implement effective **March 1, 2021** for orally administered Direct Acting Antivirals (DAAs) used in the current treatment of chronic Hepatitis C infection for Medicaid [Fee for Service (FFS) and managed care (MCO)] enrolled beneficiaries.

Background

Eliminating Hepatitis C is a District-wide goal, and enabling access to curative treatment is a critical step in achieving equitable outcomes for Medicaid beneficiaries. Currently, the District of Columbia's Medicaid program requires patients to have a fibrosis score of F2 or higher to access Hepatitis C curative treatments. Determinations are made on a case-by-case basis through the prior authorization process.

New Policy

DHCF is making the following change to its Hepatitis C Treatment Coverage Policy:

- **Elimination of the minimum fibrosis score requirement for preferred orally administered Direct Acting Antiviral medications:**
 - Mavyret® (glecaprevir and pibrentasvir)
 - Vosevi® (sofosbuvir, velpatasvir, and voxilaprevir)

For MCO Enrollees: MCOs are required to follow the policy changes published in this transmittal. Contact the appropriate MCO for more information:

- AmeriHealth Caritas DC Provider Services: 202-408-2237 or 1-888-656-2383
- CareFirst Community Health Plan DC Provider Services: 202-821-1100

- MedStar Family Choice-DC Provider Services: 855-798-4244
- Health Services for Children with Special Needs (HSCSN) Provider Services: 202-467-2737 | Option #2

Contact

If you have any questions or have any problems with obtaining medication after the change becomes effective on March 1, 2021, please contact the DHCF Division of Clinician, Pharmacy, and Acute Provider Services: Charlene Fairfax, Senior Pharmacist at (202) 442-9076 or charlene.fairfax@dc.gov; Gidey Amare, Pharmacist at (202) 442-5952 or gidey.amare@dc.gov; Jonas Terry, Pharmacist at (202) 478-1415 or jonas.terry@dc.gov; or Magellan (Pharmacy Benefit Manager) at 1-800-273-4962 (Provider Phone Line).

cc: Medical Society of the District of Columbia
DC Hospital Association
DC Primary Care Association
DC Health Care Association
DC Home Care Association
DC Behavioral Health Association
DC Coalition of Disability Service Providers